Presentations & Events
Spotlight on Recent Biodesix Presentations
December 2023 | CHEST Journal
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules - A Subgroup Analysis Comparing Screen Detection, Sex, Smoking History, and Nodule Size
Authors:
Katheryn J. Long, Trevor Pitcher, PhD. (Biodesix), Jonathan S. Kurman, MD. Michael A. Pritchett, DO. Gerard A. Silvestirti, MD.
May 2025 | ISPOR 2025 + ATS 2025
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS.
“Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States” by Kimberly Le, Biodesix Director of Health Economics and Outcomes Research at ISPOR 2025.
“Utilization of Proteomic Testing in Pulmonary Nodule Risk Stratification at a Safety-Net Hospital: An Observational Study” by Sonu Sahni, MD, Director of Lung Cancer Screening at Wyckoff Heights Medical Center in New York at the ATS 2025 Conference
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS.
“Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States” by Kimberly Le, Biodesix Director of Health Economics and Outcomes Research at ISPOR 2025.
“Utilization of Proteomic Testing in Pulmonary Nodule Risk Stratification at a Safety-Net Hospital: An Observational Study” by Sonu Sahni, MD, Director of Lung Cancer Screening at Wyckoff Heights Medical Center in New York at the ATS 2025 Conference
May 2025 | ASCO 2025
Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC
Presented by:
Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone’s Perlmutter Cancer Center
Upcoming Biodesix Presentations and Events
June 26 – 28, 2025 | Nashville, TN | 2nd Annual APAPP National Conference
August 14 – 16, 2025 | Austin, TX | AABIP 6th Annual Conference
September 22 – 25, 2025 | Boston, MA | 15th Annual World CB & CDx Summit
October 9 – 11, 2025 | Denver, CO | Go2 2025 Centers of Excellence Summit
October 19 – 22, 2025 | Chicago, IL | CHEST 2025
October 29, 2025 | Denver, CO | Mountain West BioLife Summit
Presentation and panel hosted by Brianna Phillips, VP Quality & Regulatory, Biodesix
November 7 – 8, 2025 | Charlotte, NC | Atrium Health & SAB Lung Nodule ConferenceView Past Biodesix Presentations and Events
ISPOR 2025
Life Sciences - In Focus: Laboratory Developed Tests: What Now, Where Next?
ATS 2025 International Conference
Poster presentation by Kimberly Le, PharmD, Director of HEOR, on Time to Diagnosis of Lung Cancer From Identification of a Pulmonary Nodule in the United States.
Life Sciences - In Focus: Laboratory Developed Tests: What Now, Where Next?
Panel Discussion with Tristin Wolff Cope, Director of Regulatory Compliance. Sponsored by Vistatec and RAPS Colorado Chapter.
ATS 2025 International Conference
American Association for Cancer Research Annual Meeting 2025
Spotlight theater presentation featuring Gary Pestano, Ph.D., Chief Development Officer, Biodesix on Developing Multi-Modal MRD and ctDNA Tests for Use in Clinical Research: Droplet Digital PCR-Driven Mutations and Methylation Quantification, CTCs and Proteomics. – Sponsored by Bio-Rad Laboratories.
9th Annual Liquid Biopsy for Precision Oncology Summit
Panel Discussion moderated by Matthew Pink Vice President of Business Development, Biodesix: Harnessing MRD & ctDNA to Inform Clinical Trial Decision Making & Improve Dosage Regimens
Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: Empowering Precision Oncology & MRD Monitoring through ctDNA & CTC Analysis – Sponsored by Bio-Rad Laboratories.
Friends of Cancer Research Advancing the Future of Diagnostics and Regulatory Innovations White Paper co-authored Gary Pestano, Ph.D., Chief Development Officer, Biodesix and Brianna Phillips, Vice President of Quality and Regulatory Affairs, Biodesix: Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications
Friends of Cancer Research Advancing the Future of Diagnostics and Regulatory Innovations White Paper co-authored Gary Pestano, Ph.D., Chief Development Officer, Biodesix and Brianna Phillips, Vice President of Quality and Regulatory Affairs, Biodesix: Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications
AMP 2024 Annual Meeting & Expo
Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: Droplet Digital PCR (ddPCR) in Precision Oncology and MRD: Perspectives from the Trenches
Poster Presentation by Leisa Jackson, Staff Scientist, Biodesix & Gary Pestano, Ph.D., Chief Development Officer, Biodesix: TT037 Development of a Clinical-Grade Droplet Digital PCR Workflow for Blood-Based Detection of Cancer Relevant miRNAs
Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc.
ISPOR Europe 2024 Poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix:
AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation Poster Presentation by Colin McDowell, Ph.D. Senior Manager of Business Development, Biodesix: A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics
ISPOR Europe 2024 Poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix:
- EPH31: Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)
- EPH93: Prevalence of Pulmonary Nodules (PNs) in 2020 During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)
- EE438: Economic Impact Model to Estimate the Value of Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNS) From a Health System Perspective
- EPH208: Prevalence of Pulmonary Nodules (PNs) in 2019 in the United States (US)
- EHP209: Incidence of Pulmonary Nodules (PNs) in 2019 in the United States (US)
- CO183: Clinical Impact Model for Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNs) From a Health System Perspective
AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation Poster Presentation by Colin McDowell, Ph.D. Senior Manager of Business Development, Biodesix: A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics
CHEST 2024 Annual Meeting
CHEST Learning Theater Presentation by Sonali Sethi, MD, FCCP, Pulmonary Medicine, Cleveland Clinic and D. Kyle Hogarth, MD, FCCP, Professor of Medicine, University of Chicago: “Patient impact & case studies - the real-world value of biomarkers in lung nodule management”
Go2 for Lung Cancer Centers of Excellence (COE) Summit
Droplet Digital PCR World 2024 Asia Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: From Feasibility to Clinical Testing for Rare Variants in Oncology: 10 years of ddPCR Experiences
Droplet Digital PCR World 2024 Asia Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: From Feasibility to Clinical Testing for Rare Variants in Oncology: 10 years of ddPCR Experiences